KR12 also induced significant tumor growth suppression in xenograft models, with low host toxicity in KRAS-mutated but not wild-type tumors, thus representing a promising agent against RAS mutated CRC with encouraging pre-clinical data. Here, KRAS is linked to neoplasm.